Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
Accession Number
DB10342
Description

Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen is a vaccine containing outer membrane antigen extracted from Haemophilus influenzae.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Haemophilus influenzae b (Ross strain) capsular polysaccharide Meningococcal Protein Conjugate Vaccine

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Abatacept.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen is combined with Acetylsalicylic acid.
AdalimumabThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Altretamine.
Aminosalicylic acidThe risk or severity of adverse effects can be increased when Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen is combined with Aminosalicylic acid.
AmsacrineThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen can be decreased when used in combination with Anakinra.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
PedvaxHIBInjection, suspension7.5 ug/0.5mLIntramuscularMerck Sharp & Dohme Corp.1989-12-20Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ComvaxHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (7.5 ug/0.5mL) + Hepatitis B virus subtype ADW HBSAG surface protein antigen (5 ug/0.5mL)Injection, suspensionIntramuscularMerck Sharp & Dohme Limited1996-10-022016-08-19US flag
VaxelisHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (3 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Hepatitis B virus subtype ADW HBSAG surface protein antigen (10 ug/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (29 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (7 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (26 [D'ag'U]/0.5mL)Injection, suspensionIntramuscularMCM Vaccine Co.2018-12-212020-04-10US flag
VaxelisHaemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen (3 ug/0.5mL) + Bordetella pertussis filamentous hemagglutinin antigen (formaldehyde inactivated) (20 ug/0.5mL) + Bordetella pertussis fimbriae 2/3 antigen (5 ug/0.5mL) + Bordetella pertussis pertactin antigen (3 ug/0.5mL) + Bordetella pertussis toxoid antigen (glutaraldehyde inactivated) (20 ug/0.5mL) + Clostridium tetani toxoid antigen (formaldehyde inactivated) (5 [Lf]/0.5mL) + Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (15 [Lf]/0.5mL) + Hepatitis B virus subtype ADW HBSAG surface protein antigen (10 ug/0.5mL) + Poliovirus type 1 antigen (formaldehyde inactivated) (29 [D'ag'U]/0.5mL) + Poliovirus type 2 antigen (formaldehyde inactivated) (7 [D'ag'U]/0.5mL) + Poliovirus type 3 antigen (formaldehyde inactivated) (26 [D'ag'U]/0.5mL)Injection, suspensionIntramuscularMSP Vaccine Company2018-12-21Not applicableUS flag

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
LUY6P8763W
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910521
RxNav
798444

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionHepatitis A Virus1
4Not Yet RecruitingPreventionDiphtheria1
3Active Not RecruitingTreatmentInfections, Pneumococcal1
3CompletedPreventionBacterial Infections / Neisseria Meningitidis / Virus Diseases2
3CompletedPreventionBacterial Infections / Virus Diseases2
3CompletedPreventionHaemophilus Influenza b Infections / Haemophilus Influenzae Type B / Meningococcal Infections / Neisseria Meningitidis / Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine1
3CompletedPreventionHaemophilus Influenzae Type B / Haemophilus Influenzae Type B Infection / Meningococcal Infections / Neisseria Meningitidis1
3CompletedPreventionHaemophilus Influenzae Type B / Neisseria Meningitidis1
3CompletedPreventionHaemophilus Influenzae Type B / Viral Hepatitis B1
3CompletedPreventionMumps / Rubella / Rubeola / Varicella1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular
Injection, solutionIntramuscular20 IU
InjectionIntramuscular10 µg
Injection, powder, for suspensionIntramuscular10 mcg
Injection, suspensionIntramuscular7.5 ug/0.5mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 13:03 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates